Ozmosi | Alvocidib Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

Alvocidib

Alternative Names: alvocidib, flavopiridol, flavopiridol (alvocidib)
Clinical Status: Inactive
Latest Update: 2024-03-01
Latest Update Note: PubMed Publication

Product Description

Alvocidib is a synthetic dihydroxyflavone that is 5,7-dihydroxyflavone which is substituted by a 3-hydroxy-1-methylpiperidin-4-yl group at position 8 and by a chlorine at the 2' position (the (-)-3S,4R stereoisomer). A cyclin-dependent kinase 9 (CDK9) inhibitor, it has been studied for the treatment of acute myeloid leukaemia, arthritis and atherosclerotic plaque formation. It has a role as an antineoplastic agent, an EC 2.7.11.22 (cyclin-dependent kinase) inhibitor, an antirheumatic drug and an apoptosis inducer. It is a dihydroxyflavone, a hydroxypiperidine, a member of monochlorobenzenes and a tertiary amino compound. It is a conjugate base of an alvocidib(1+). (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Alvocidib)

Mechanisms of Action: CDK9 Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Sanofi
Company Location: Europe
Company Founding Year: 1973
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: Diffuse Large B-Cell Lymphoma|Mantle-Cell Lymphoma|Waldenstrom Macroglobulinemia|Leukemia, Plasma Cell|Sezary Syndrome|Large-Cell Anaplastic Lymphoma|Immunoblastic Lymphadenopathy|Prolymphocytic Leukemia|Ovarian Cancer|Multiple Myeloma|Mycosis Fungoides|Large-Cell Immunoblastic Lymphoma|B-Cell Marginal Zone Lymphoma|Lymphomatoid Granulomatosis|Lymphocytic Chronic B-Cell Leukemia|Squamous Cell Carcinoma|Peritoneal Cancer|Adenocarcinoma|Prolymphocytic B-Cell Leukemia|Pancreatic Cancer|Renal Cell Carcinoma|Breast Cancer|Follicular Lymphoma|T-Cell Cutaneous Lymphoma|Lymphoma, Non-Hodgkin|Chronic Lymphoid Leukemia|Acute Myeloid Leukemia|Adult T-Cell Leukemia-Lymphoma|Multiple Sclerosis|Head and Neck Cancer|Kidney Cancer|Thromboembolism|Melanoma|Acute Megakaryoblastic Leukemia|Acute Monocytic Leukemia|Acute Myelomonocytic Leukemia|Acute Erythroblastic Leukemia|Lymphoma, B-Cell|Endometrial Cancer|Prostate Cancer|Esophageal Cancer|Myelodysplastic Syndrome|Sarcoma|Germinoma|Testicular Cancer|Seminoma|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Liver Cancer|Preleukemia|Acute Eosinophilic Leukemia|Hypereosinophilic Syndrome|Acute Lymphoid Leukemia|Acute Basophilic Leukemia|Gastrointestinal Cancer

Phase 1: Chronic Lymphoid Leukemia|Lymphoma, B-Cell|Breast Cancer|Skin Cancer|Melanoma|Oncology Solid Tumor Unspecified|Prostate Cancer|Ependymoma|Sarcoma, Ewing|Lymphocytic Chronic B-Cell Leukemia|Kidney Cancer|Optic Nerve Cancer|Retinoblastoma|Optic Nerve Glioma|Supratentorial Cancer|Primitive Neuroectodermal Tumors|Peripheral Neuroectodermal Tumors, Primitive|Kidney Diseases|Leukemia|Lymphoma|Lymphoma, Non-Hodgkin|Neuroblastoma|Liver Cancer|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Intestinal Cancer|Brain Stem Cancer|Wilms Tumor|Acute Myeloid Leukemia|Acute Megakaryoblastic Leukemia|Osteosarcoma|Astrocytoma|Embryonal Rhabdomyosarcoma|Medulloblastoma|Cerebellar Cancer|Hypothalamic Cancer|Soft Tissue Cancer|Lymphoid Leukemia|Acute Erythroblastic Leukemia|Pancreatic Cancer|Prolymphocytic Leukemia|Thrombocytopenia|Acute Lymphoid Leukemia|Blast Crisis|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Adenocarcinoma|Acute Eosinophilic Leukemia|Non-Small-Cell Lung Cancer|Hypereosinophilic Syndrome|Acute Monocytic Leukemia|Follicular Lymphoma|Anemia, Refractory, with Excess of Blasts|Multiple Myeloma|Mesothelioma|Chronic Myeloid Leukemia|Acute Basophilic Leukemia|B-Cell Marginal Zone Lymphoma|Chronic Myelomonocytic Leukemia|Mantle-Cell Lymphoma|Waldenstrom Macroglobulinemia|Male Breast Cancer|Lymphoproliferative Disorders|Esophageal Cancer|Diffuse Large B-Cell Lymphoma|Anemia, Refractory|Oncology Hematological Unspecified|Prolymphocytic B-Cell Leukemia|Hairy Cell Leukemia|Acute Myelomonocytic Leukemia|Gastrointestinal Stromal Tumors|Sarcoma

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT03441555

M16-186

P1

Completed

Acute Myeloid Leukemia

2021-01-25

25%

2023-10-18

Primary Endpoints|Treatments

JapicCTI-183964

JapicCTI-183964

P1

Unknown

Acute Myeloid Leukemia

2020-03-31

NCT03563560

AML

P1

Completed

Acute Myeloid Leukemia

2020-03-31

32%

2024-11-27

Primary Endpoints|Treatments

NCT03298984

TPI-ALV-101

P1

Completed

Acute Myeloid Leukemia

2020-03-20

16%

2024-11-27

Primary Endpoints|Treatments

NCT00094978

05-C-0010

P1

Terminated

Esophageal Cancer|Mesothelioma|Non-Small-Cell Lung Cancer

2013-05-20

2019-03-21

Treatments

NCT00735930

NCI-2009-00269

P1

Completed

Lymphocytic Chronic B-Cell Leukemia|Chronic Lymphoid Leukemia|Anemia, Refractory|Prolymphocytic B-Cell Leukemia|Prolymphocytic Leukemia|Lymphoma, B-Cell|Thrombocytopenia

2013-03-01

2019-03-18

Treatments

NCT00101231

NCI-2012-01461

P1

Terminated

Acute Eosinophilic Leukemia|Chronic Lymphoid Leukemia|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Acute Myelomonocytic Leukemia|Chronic Myelomonocytic Leukemia|Acute Monocytic Leukemia|Acute Myeloid Leukemia|Acute Megakaryoblastic Leukemia|Blast Crisis|Acute Lymphoid Leukemia|Chronic Myeloid Leukemia|Hypereosinophilic Syndrome|Acute Basophilic Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Erythroblastic Leukemia

2012-11-01

2019-03-21

Treatments

NCT00377104

NCI-2009-00161

P1

Terminated

Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia|Lymphoma, B-Cell

2012-11-01

2019-03-21

Treatments

NCT00082784

NCI-2009-00058

P1

Completed

Waldenstrom Macroglobulinemia|Follicular Lymphoma|Mantle-Cell Lymphoma|Lymphoma, Non-Hodgkin|Diffuse Large B-Cell Lymphoma|Multiple Myeloma|B-Cell Marginal Zone Lymphoma

2012-10-01

2019-03-21

Treatments

NCT00112684

NCI-2009-00135

P1

Terminated

Oncology Solid Tumor Unspecified

2012-07-01

2019-03-21

Treatments

NCT00098579

NCI-2009-00048

P1

Completed

Sarcoma|Gastrointestinal Stromal Tumors

2011-07-01

2024-11-27

Primary Endpoints|Treatments

NCT00470197

NCI-2009-00243

P1

Completed

Acute Lymphoid Leukemia|Acute Monocytic Leukemia|Acute Myelomonocytic Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Megakaryoblastic Leukemia|Acute Myeloid Leukemia|Acute Erythroblastic Leukemia

2011-01-01

2024-11-27

2017-001178-41

2017-001178-41

P2

Terminated

Acute Myeloid Leukemia

2021-10-10

2022-03-13

Treatments

NCT03593915

TPI-ALV-102

P2

Terminated

Myelodysplastic Syndrome|Preleukemia

2021-08-16

13%

2023-10-18

Primary Endpoints

NCT03969420

TPI-ALV-202

P2

Terminated

Acute Myeloid Leukemia

2021-04-22

36%

2023-10-18

NCT04493099

NCI-2020-05266

P2

Withdrawn

Acute Myeloid Leukemia

2020-10-12

2020-11-13

NCT02520011

TPI-ALV-201

P2

Terminated

Acute Myeloid Leukemia

2020-02-12

70%

2024-11-27

Primary Endpoints

NCT00634244

NCI-2009-00520

P2

Completed

Acute Myelomonocytic Leukemia|Acute Myeloid Leukemia|Acute Erythroblastic Leukemia|Acute Monocytic Leukemia|Acute Megakaryoblastic Leukemia

2014-09-01

2024-11-27

Primary Endpoints|Treatments

NCT00957905

NCI-2011-01405

P2

Completed

Testicular Cancer|Germinoma|Ovarian Cancer|Seminoma

2014-08-01

2025-02-07

Primary Endpoints|Treatments

NCT01349972

NCI-2011-02587

P2

Completed

Acute Myeloid Leukemia|Acute Erythroblastic Leukemia|Acute Myelomonocytic Leukemia|Myelodysplastic Syndrome|Acute Monocytic Leukemia

2014-05-01

2024-11-27

Primary Endpoints|Treatments

NCT00445341

07-C-0081

P2

Completed

Mantle-Cell Lymphoma|Diffuse Large B-Cell Lymphoma

2012-04-30

2019-03-21

NCT00991952

NCI-2011-03825

P2

Completed

Adenocarcinoma|Gastrointestinal Cancer|Esophageal Cancer

2012-02-01

2024-11-27

Primary Endpoints|Treatments

2006-006152-34

2006-006152-34

P2

Completed

Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia|Prolymphocytic Leukemia|Prolymphocytic B-Cell Leukemia

2012-01-16

2022-03-12

Treatments

NCT00464633

EFC6663

P2

Completed

Prolymphocytic B-Cell Leukemia|Prolymphocytic Leukemia|Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia

2011-12-01

2019-03-21

Treatments

NCT00112723

NCI-2011-01346

P2

Terminated

Chronic Lymphoid Leukemia|Follicular Lymphoma|Diffuse Large B-Cell Lymphoma|Leukemia, Plasma Cell|Waldenstrom Macroglobulinemia|Mantle-Cell Lymphoma|T-Cell Cutaneous Lymphoma|Lymphoma, Non-Hodgkin|Immunoblastic Lymphadenopathy|Large-Cell Anaplastic Lymphoma|Sezary Syndrome|Multiple Myeloma|Adult T-Cell Leukemia-Lymphoma|Mycosis Fungoides|Large-Cell Immunoblastic Lymphoma|Lymphocytic Chronic B-Cell Leukemia|Multiple Sclerosis|Lymphomatoid Granulomatosis|B-Cell Marginal Zone Lymphoma

2011-02-01

2020-10-26

Primary Endpoints